Internal Medicine News - Trial data added to coreg label
The label of Coreg (carvedilol) has been changed to include data from two clinical trials that show reduced risk of repeat MI and reduced risk of MI in heart failure patients. Patients participating the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study experienced a 40% reduction in fatal or nonfatal MI. According to the trial results, when carvedilol was initiated within 21 days and maintained long term in patients following an MI that damaged the heart, the risk of dying was reduced by 23%.
Related Results
New indications for once-daily CoregFlamel Technologies Welcomes FDA Approval of COREG CR™Flamel Technologies Welcomes Nationwide Availability of COREG CR™New & approved: Coreg biotronik home monitoring systemGSK unveils more convenient form of Coreg, targets oncology
In the Carvedilol or Metoprolol European Trial (COMET) 3,029 patients with heart failure were randomized to receive either carvedilol or immediate-release metolprolol tartrate. All-cause mortality was 34% in the patients treated with carvedilol, compared with 40% in the metoprolol-tartrate group.
For more information, contact GlaxoSmithKline by calling 888-825-5249 or by visiting www.gsk.com.
COPYRIGHT 2005 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
